US Material Events SEC 8-K Filings — July 29, 2026

29-07-2026

VF Corp reported Q1 FY27 results that beat guidance, with revenue ex-Dickies up 1% YoY (flat constant currency) and adjusted operating loss of $95M slightly better than the $100M guidance. However, reported revenue declined 5% YoY, and Vans continued to struggle with an 8% decline (9% constant currency), as DTC growth was more than offset by wholesale declines. The company raised its FY27 revenue guidance to +2% or better constant currency, and announced a CFO transition with Abhishek expanding to CFO and COO.

• · The North Face Americas grew 8% vs. LY, with growth across both channels.
• · Vans Americas DTC continued to grow but was more than offset by global wholesale declines; Vans wholesale expected to improve significantly in H2 FY27.
• · Timberland Americas grew 11% vs. LY (10% constant currency).
• · Altra grew double-digits across regions and channels.
• · Smartwool grew double-digits vs. LY across DTC and wholesale.
• · Napapijri reset underway as planned, capitalizing on the road to the 2027 America's Cup in Naples.
• · Packs (JanSport, Kipling, Eastpak) up vs. LY driven by growth at JanSport and Kipling ahead of back-to-school.
• · FY27 free cash flow guidance flat to up vs. FY26's $405M, excluding $100M net pension termination impact in FY26 and any tariff refunds in FY27.
• · FYE27 leverage ratio target of 2.6x to 2.9x.
• · The company does not provide reconciliation of forward-looking non-GAAP measures due to inherent difficulty in forecasting certain items.

29-07-2026

Lemonade, Inc. announced the transition of CFO Tim Bixby to a Class III Board member effective January 1, 2027, and the appointment of Nick Stead, currently SVP Finance, as the new CFO effective the same date. The filing contains no financial metrics or period-over-period comparisons, only organizational changes.

• · Tim Bixby's transition to the Board is effective January 1, 2027.
• · Nick Stead joined Lemonade in December 2019 as Director FP&A and was promoted to Senior Director FP&A and Investor Relations in September 2020.
• · Stead served as SVP, Finance and Business Operations at Flex from February 2022 through March 2023 before returning to Lemonade as VP Finance in March 2023.
• · Stead was promoted to SVP Finance in July 2024.
• · Stead played an instrumental role in Lemonade's IPO, secondary offering, a strategic acquisition, and sales/marketing growth financing arrangements.
• · Material terms of Bixby's transition and Stead's compensation will be disclosed in an amendment to this 8-K.

29-07-2026

Nuvve Holding Corp. filed an 8-K on July 29, 2026, disclosing the automatic termination of its Common Shares Purchase Agreement (ELOC Agreement) with Five Narrow Lane, L.P. and Hailstone Peak Funding LLC, effective July 24, 2026. The termination was triggered by the delisting of Nuvve's common stock from Nasdaq, which occurred on July 24, 2026. The company incurred no early termination penalties as a result of the termination.

• · The ELOC Agreement was originally dated November 14, 2025, and amended on December 1, 2025.
• · The delisting from Nasdaq occurred effective July 24, 2026.
• · The company's common stock trades on the OTC Pink Limited Market under the symbol NVVE.

29-07-2026

Westin Acquisition Corp (Nasdaq: WSTNU) announced a definitive business combination agreement with First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) to create a publicly traded healthcare and wellness company. The transaction values First Choice at a pro forma enterprise value of approximately $650 million and is expected to close in Q4 2026. The combined company will rebrand as Wellgevity 360, focusing on longevity, preventative care, and personalized medicine, and will trade on Nasdaq.

• · The transaction implies a pre-money equity value of approximately $650 million for First Choice Healthcare.
• · The combined company is expected to trade on Nasdaq.
• · Transaction expected to close in Q4 2026, subject to regulatory and shareholder approvals.
• · Westin will domesticate from the Cayman Islands to Nevada prior to closing.
• · The global wellness economy is forecast to reach $9.8 trillion by 2029 at a 7.6% annual growth rate.
• · Millennials and Gen Z are driving a 'prejuvenation' trend in the wellness market.
• · The business model emphasizes cash-pay services to reduce insurance dependency and membership programs for recurring revenue.

29-07-2026

American Airlines, Inc. announced the pricing of a $1.325 billion enhanced equipment trust certificate (EETC) offering on July 27, 2026, comprising $1,051,470,000 in Class A certificates and $273,912,000 in Class B certificates. The offering is underwritten by Deutsche Bank Securities Inc. and Citigroup Global Markets Inc. This is a routine debt financing transaction secured by aircraft assets, with no negative or flat performance metrics disclosed in the filing.

• · The underwriting agreements were entered into on July 27, 2026.
• · The filing includes consents from three aircraft appraisal firms for both Class A and Class B certificates.
• · The registrant is incorporated in Delaware with IRS Employer Identification No. 13-1502798.

29-07-2026

Reliance Global Group, Inc. (RELIW) announced on July 27, 2026 that its Compensation Committee approved the accelerated vesting of restricted stock awards granted on June 24, 2026 under the 2025 Equity Incentive Plan. The unvested portion of these awards vested in full on July 27, 2026, benefiting certain employees, named executive officers, and directors. The company stated the accelerations are intended to further retention objectives, align management with shareholder value creation, and recognize past contributions.

• · The accelerated vesting applies only to awards granted on June 24, 2026, which were originally scheduled to vest over time.
• · The amendments were approved by the Compensation Committee, not the full Board.
• · The filing does not disclose the total number of shares accelerated for all employees combined.

29-07-2026

Rising Dragon Acquisition Corp. (RDACU) issued a $55,637.41 promissory note to SZG Limited on June 15, 2026, to extend the time available to consummate its initial business combination. The note is non-interest bearing and convertible into private units at $10.00 per unit upon closing of the business combination. If the merger agreement is terminated under certain conditions or the business combination does not close, the note will be terminated with no amounts due.

• · The note is dated June 15, 2026, and the initial public offering prospectus is dated October 10, 2024.
• · The merger agreement with SZG Limited and other parties was signed on January 27, 2025.
• · Proceeds from the note must be deposited into the trust account to extend the time for the business combination.
• · No interest accrues on the note.
• · The note is governed by New York law and the parties waive jury trial rights.
• · The payee (SZG Limited) waives any claim against the trust account, limiting recourse to assets outside the trust.

29-07-2026

PetVivo Holdings, Inc. has terminated its exclusive license and supply agreement with VetStem, Inc. for the PrecisePRP™ Canine and Equine products, effective July 24, 2026, following undisclosed disputes. As part of the settlement, PetVivo will pay VetStem a total of $75,000 in two installments and transfer all remaining inventory and marketing materials at no cost, while a warrant for 250,000 shares of PetVivo common stock held by VetStem remains in full force. The termination eliminates all future royalty and revenue streams from these products, representing a significant negative development for PetVivo's business operations.

• · The License Agreement was originally dated February 13, 2025, and had been amended twice (February 26, 2025 and August 14, 2025).
• · No sell-through period was implemented; all sales by PetVivo ceased on the Effective Date.
• · VetStem retains a warrant to purchase up to 250,000 shares of PetVivo common stock (Warrant PET-216), which remains in full force and effect.
• · Both parties agreed to a mutual release of all claims related to the License Agreement and a 5-year non-disparagement clause.
• · PetVivo must refer any adverse events related to the products to VetStem within 2 business days for FDA compliance.
• · The agreement includes a per-vial shortfall fee (amount redacted) if inventory transferred is less than the minimums stated in Article 3.

29-07-2026

Dynatrace announced the appointment of AI and technology leader Chandu Thota to its Board of Directors effective July 27, 2026. Mr. Thota brings over 20 years of experience from Google, Microsoft, and DeepMind, and currently serves as VP of Engineering at Google Workspace. The company sees his expertise as valuable for advancing its AI-powered observability strategy.

• · Mr. Thota holds a Bachelor of Engineering in Electrical Engineering from Osmania University.
• · His previous leadership roles at Alphabet include VP of the Product Unit/Applied AI group at Google DeepMind, VP of Business Platforms for Google Cloud, and VP of Engineering for Google Maps.
• · Prior to joining Alphabet, he was a founder and CTO of a start-up that was acquired by Google, and held key engineering roles at Microsoft.
• · Mr. Thota holds numerous patents in mobile, web, local search, and mapping technologies, and has authored two technical books.

29-07-2026

Fortrea reported Q2 2026 revenue of $678.2M, down 4.5% YoY from $710.3M, but narrowed its GAAP net loss to $(13.2)M from $(374.9)M (which included a $309.1M goodwill impairment). Adjusted EBITDA rose 6.9% to $58.7M and adjusted EPS improved to $0.23 from $0.19. The company raised full-year 2026 guidance, reflecting confidence in its turnaround, though revenue remains below prior-year levels.

• · Book-to-bill ratio for Q2 2026 was 1.06x, and 1.12x for the trailing twelve months.
• · Backlog stood at $7,800 million as of June 30, 2026.
• · Full-year 2026 guidance raised: revenue $2,620M to $2,690M; adjusted EBITDA $205M to $220M.
• · Cash and cash equivalents decreased to $168.6M from $174.6M at year-end 2025.
• · Total debt (current + long-term) was $1,054.3M, up slightly from $1,052.8M at year-end 2025.
• · Accumulated deficit widened to $(1,420.0)M from $(1,383.2)M at year-end 2025.

29-07-2026

Procter & Gamble announced that Shailesh Jejurikar, currently President and CEO, will also become Chairman of the Board effective August 1, 2026, succeeding Jon Moeller, who will retire as Executive Chairman on July 31, 2026 and leave the company on August 14, 2026. Moeller served 38 years at P&G, including roles as Executive Chairman, CEO, COO, and CFO. The leadership transition is orderly and pre-planned, with no financial results or performance metrics disclosed.

• · Shailesh Jejurikar joined P&G in 1989 and has been on the global leadership team since 2014.
• · Jejurikar has led global Fabric Care and Home Care businesses across North America, Europe, Asia, and Latin America.
• · Jon Moeller's retirement from the Board is effective July 31, 2026, and from P&G effective August 14, 2026.
• · P&G operates in approximately 70 countries worldwide.

29-07-2026

CID HoldCo, Inc. (DAICW) disclosed on July 29, 2026 that the lead investor terminated a Securities Purchase Agreement dated July 22, 2026, citing alleged breaches of closing conditions and representations. The company disputes the termination and is evaluating its legal options and creditor alternatives. The collapse of this financing deal, which involved the issuance of Series AA and Series B convertible preferred stock, creates significant uncertainty about the company's near-term liquidity and strategic plans.

• · The Purchase Agreement was entered into on July 22, 2026 and terminated on July 27, 2026.
• · The termination also scuttles related agreements: Registration Rights Agreement, Voting Agreement, and Employment Agreement.
• · The company is exploring options for its creditors, indicating potential financial distress.
• · The company's common stock (DAIC) and warrants (DAICW) trade on Nasdaq; warrants have an exercise price of $287.50 per share (post-reverse stock split).
• · The company is an emerging growth company and has elected not to use the extended transition period for new accounting standards.

29-07-2026

Stepan Company reported strong Q2 2026 results with net income up 102% YoY to $22.9M and adjusted EBITDA up 45% to $74.4M, driven by Surfactant and Polymer volume growth and margin recovery. However, the first half of 2026 showed a net loss of $18.5M due to a $70.5M pre-tax restructuring charge, and free cash flow was negative $15.0M in the quarter due to higher working capital. The company announced a plan to reduce its global salaried workforce by approximately 100 positions as part of Project Catalyst, with full-year restructuring charges expected between $75.0M and $80.0M.

• · Q2 2026 Surfactant organic sales volume up 7% YoY with broad-based growth across all end markets and regions.
• · Q2 2026 Polymer North American sales volume up double digits, including significant growth in Spray Foam, partially offset by lower volumes in Europe and Asia.
• · Specialty Products adjusted EBITDA declined 3% in Q2 and 8% in the first half due to less favorable product mix in medium chain triglycerides.
• · First half 2026 Polymer net sales were flat YoY at $308.0M vs $308.9M.
• · Corporate expenses surged 232% in the first half to $106.3M, largely due to restructuring charges.
• · The company expects full year restructuring charges of $75-80M with cash impact of $14-18M.
• · The company anticipates full year Adjusted EBITDA growth, positive free cash flow, and continued deleveraging in 2026.

29-07-2026

Core Scientific appointed Mark W. Adams to its Board of Directors, expanding the board to seven members. Mr. Adams brings over 30 years of technology leadership experience, including as CEO of Penguin Solutions and senior roles at Micron Technology, and currently serves on the boards of Seagate Technology and Cadence Design Systems. The filing contains no financial results or period-over-period comparisons, so no positive or negative performance metrics are available.

• · Mr. Adams served as President and CEO of Penguin Solutions from 2020 to 2026, leading a repositioning toward AI infrastructure solutions.
• · He spent ten years at Micron Technology, including four years as President.
• · He holds an MBA from Harvard University and a B.A. from Boston College.
• · Core Scientific operates data centers in Alabama (1), Georgia (2), Kentucky (1), North Carolina (1), North Dakota (1), Oklahoma (1), and Texas (4).
• · The company is repurposing its remaining mining facilities to support high-density colocation services.

29-07-2026

Bandwidth Inc. reported strong Q2 2026 results with revenue of $220M (up 22% YoY) and Adjusted EBITDA of $28M (up 27% YoY), achieving a record Adjusted EBITDA margin of 18%. However, GAAP gross margin declined from 40% to 36% YoY, and net cash from operations decreased from $32M to $29M in the quarter. The company raised its full-year 2026 guidance, citing AI-driven demand and enterprise customer wins.

• · GAAP gross margin declined from 40% to 36% YoY in Q2 2026.
• · Net cash from operating activities decreased from $32M to $29M YoY in Q2 2026.
• · Free cash flow decreased from $26M to $24M YoY in Q2 2026.
• · Non-GAAP net income per share was flat at $0.38 in Q2 2025 vs $0.37 in Q2 2026.
• · Full-year 2026 revenue guidance raised to $900M-$910M, and Adjusted EBITDA guidance raised to $123M-$125M.
• · Q3 2026 revenue guidance is $231M-$235M, with Adjusted EBITDA of $32M-$34M.
• · Each $1M+ customer win in Q2 included Maestro or AI services.
• · A long-standing global hyperscaler partner significantly expanded its use of Bandwidth for a key digital service internationally.
• · One of the largest U.S. text messaging platforms consolidated more than 95% of its messaging traffic onto Bandwidth's platform.

29-07-2026

Humana Inc. elected Paul Smith (Chief Commercial Officer at Anthropic) and Frederick Crawford (former President/COO of Aflac) to its Board of Directors, effective immediately. The appointments bring technology/AI expertise and deep insurance industry financial experience to the board, expanding its size to 13 directors. No negative or flat metrics are present as this is a governance update.

• · Paul Smith brings over 30 years of experience in enterprise technology go-to-market strategies, including roles at ServiceNow, Salesforce, and Microsoft.
• · Frederick Crawford served as CFO of three publicly traded insurers (Aflac, CNO Financial Group, Lincoln Financial Group) and later as President/COO of Aflac until 2024.
• · Crawford sits on the board of Webster Financial Corporation, serving on Audit and Risk committees.
• · The election is effective immediately, bringing the board to 13 directors.

29-07-2026

Synlogic (OTC: SYBX) and Caldera Therapeutics have entered into a definitive all-stock merger agreement, with the combined company to operate as Caldera Therapeutics and trade on Nasdaq under the ticker 'CALD'. Concurrently, Caldera secured an upsized $278 million private placement from leading healthcare investors to fund Phase 2 trials of CLD-423, a TL1A x IL-23p19 bispecific antibody for IBD, with cash runway projected into 2029. Pre-merger Synlogic stockholders will own only ~2.3% of the combined company, while Caldera stockholders will own ~62.8% and PIPE investors ~34.9%, reflecting a significant dilution for existing Synlogic shareholders.

• · CLD-423 is a bispecific antibody targeting TL1A and IL-23p19 pathways, designed with a monovalent 1+1 format and YTE half-life extension mutation.
• · Phase 1 healthy volunteer trial in Australia commenced January 2026; dosing completed for SAD cohorts 1-4 with no dose-limiting toxicities.
• · CLD-423 demonstrated serum half-life exceeding 40 days and ~80% subcutaneous bioavailability, supporting once-every-8-or-12-week maintenance dosing.
• · Anti-drug antibody incidence was low in SAD cohorts, with late onset and low titers, indicating a favorable immunogenicity profile.
• · Caldera expects to report additional data from all five SAD cohorts and multiple-dose cohorts later in 2026.
• · Transaction expected to close by early 2027, subject to stockholder approvals and SEC registration statement effectiveness.
• · Combined company will be led by Caldera's CEO Praveen Tipirneni; Caldera's Board will become the directors of the combined company.

29-07-2026

Processa Pharmaceuticals, Inc. (PCSA) announced the acquisition of Vidya Therapeutics, Inc., adding the next-generation BTK inhibitor VT-7208 to its pipeline. Concurrently, the company secured an oversubscribed private placement of approximately $200 million from a syndicate of leading healthcare investors. The combined cash is expected to fund operations into the second half of 2029, with Phase 2 proof-of-concept data anticipated in food allergy (2H 2027), CSU (1H 2028), and RMS (2H 2028). However, existing Processa stockholders will be diluted to only about 0.9% ownership on a fully-diluted basis, while Vidya equity holders and new investors will own approximately 46.0% and 52.6%, respectively.

• · VT-7208 is a CNS-penetrant, once-daily, oral covalent BTKi designed to minimize off-target kinase activity and reduce hepatotoxicity risk relative to earlier BTKis.
• · In Phase 1, VT-7208 demonstrated robust target engagement, durable pharmacodynamic activity, and predictable dose-dependent pharmacokinetics in both CSF and periphery, with no serious adverse events.
• · Processa expects to initiate Phase 2 studies in food allergy and CSU in 2H 2026, and in RMS in 1H 2027.
• · The acquisition and private placement closings are not subject to Processa stockholder approval; stockholder approval is required only for conversion of the Series A preferred stock.
• · Processa intends to continue development of legacy assets PCS499 and PCS12852 alongside the BTK inhibitor program.

29-07-2026

Olenox Industries Inc. (formerly Safe & Green Holdings Corp.) appointed Kimberly Hawley as Interim CFO effective July 6, 2026, with an annual base salary of $250,000 and a $50,000 restricted stock grant vesting over 18 months. Ms. Hawley, age 57, brings over 30 years of financial leadership and will continue her existing role as CFO of Vivakor, Inc. The appointment is for a fixed term ending December 31, 2026, and the filing does not disclose any prior-period financial comparisons or performance metrics.

• · Employment term is from July 6, 2026 to December 31, 2026.
• · Ms. Hawley is a Certified Public Accountant (CPA) with a BBA from Loyola University Chicago and an MBA from Pepperdine University.
• · She is subject to a one-year post-termination non-compete and non-solicit.
• · No family relationships or reportable transactions under Item 404(a) were disclosed.
• · The company changed its name from Safe & Green Holdings Corp. to Olenox Industries Inc. on December 19, 2022.

29-07-2026

FHLBank Atlanta announced a series of executive leadership changes effective August 10, 2026, including Alp Can moving from Chief Risk Officer to Chief Operating Officer, and the creation of a new Chief Collateral Officer role. The changes aim to enhance operational excellence and align leadership with the Bank's mission, though they involve interim appointments and expanded responsibilities rather than departures or external hires.

• · The organizational changes go into effect August 10, 2026.
• · Cristina Cowan will serve as Interim Chief Risk Officer while the Bank conducts an internal and external search for the role.
• · Erin Martin has been named to a new role, Chief Collateral Officer, reporting to Alp Can.
• · Haig Kazazian, CFO, will assume expanded responsibilities including oversight of affordable housing and community investment and vendor management.

29-07-2026

William Garth resigned from the Board of Governors of Highwater Ethanol, LLC effective July 27, 2026. The resignation was not due to any disagreement with the company.

29-07-2026

Boot Barn Holdings, Inc. reported strong Q1 FY2027 results with net sales up 17.7% to $593.5M and same-store sales up 4.7%, driven by e-commerce growth of 13.4%. Net income rose to $70.1M ($2.29/diluted share) from $53.4M ($1.74/share) a year ago, including a $0.38/share benefit from tariff refunds. However, July same-store sales were flat (0.0%) and retail store SSS declined 1.2% in the four weeks ended July 25, 2026, signaling a moderation in momentum.

• · The company's revolving credit facility capacity was increased from $250M to $500M on July 28, 2026.
• · Average inventory per store increased approximately 1.2% on a same-store basis compared to June 28, 2025.
• · FY2027 capital expenditures guidance is $125M to $130M, net of estimated landlord tenant allowances of $47.6M.
• · The company opened 27 new stores in Q1, bringing total to 566; as of July 29, 2026, total stores are 571.
• · Q2 FY2027 guidance includes retail store same store sales declines of (1.0)% to growth of 1.0%.
• · The effective tax rate for the remaining nine months of FY2027 is expected to be 25.7%, up from 24.1% in Q1.

29-07-2026

Avalon GloboCare Corp. (now Change Agents Corporation) entered into a Business Loan and Security Agreement on July 24, 2026, securing a term loan from Agile Capital Funding, LLC and Agile Lending, LLC. The loan proceeds will be used to pay off an existing $529,400 balance and for general business purposes. The agreement grants a first-priority security interest in substantially all of the company's assets, includes a make-whole prepayment premium, and carries a default interest rate increase of 5 percentage points.

• · The loan is secured by a first-priority security interest in all of the borrower's collateral, including after-acquired property.
• · The borrower must pay a make-whole premium (Prepayment Fee) equal to all interest that would have been paid through the Maturity Date upon any prepayment.
• · Interest is computed on a 360-day year basis.
• · The default interest rate is the otherwise applicable rate plus 5.00% per annum.
• · The loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d) and cannot be reborrowed once repaid.
• · The borrower represents that there is no pending or threatened litigation involving more than $50,000, except as disclosed on the Perfection Certificate.
• · The borrower represents that there has been no Material Adverse Change since the date of the most recent financial statements submitted to any lender, except as set forth in SEC filings.

29-07-2026

Brag House Holdings, Inc. (TBH) disclosed that its subsidiary, Dogecoin Ventures, Inc., entered into an unsecured subordinated short-term note for $1,400,000 with lender Devlin DeFrancesco. The note carries a 10.714% annual interest rate and matures on July 27, 2027, with repayment to be made in shares of CleanCore Solutions, Inc. (ZONE Shares) plus accrued interest. However, repayment is subordinated to all secured creditors and is contingent on the parent company first repaying the Yorkville Loan, introducing significant repayment risk.

• · The note is unsecured and subordinated to all secured creditors, meaning the lender has no claim on assets if the borrower defaults.
• · Repayment is contingent on the parent company (House of Doge Inc.) first repaying the Yorkville Loan to YA II PN, Ltd., which introduces a condition precedent.
• · The Repayment Consideration consists of 2,227,300 shares of CleanCore Solutions, Inc. (ZONE Shares) that are currently pledged to Parentco's senior lenders, creating potential delivery risk.
• · Events of default include failure to pay within 5 business days after notice, bankruptcy, or cessation of business.
• · The note is governed by Texas law.

29-07-2026

The filing reports multiple material events for BNB PLUS CORP., including entry into and termination of material definitive agreements, unregistered sales of equity securities, and director/officer departures and appointments. No specific financial metrics, transaction values, or performance data are disclosed, limiting quantitative analysis. The filing is informational with no directional bias.

• · The filing is a multi-item 8-K covering Items 1.01, 1.02, 3.02, and 5.02.
• · No specific names, titles, dates, or financial terms are disclosed for any of the items.
• · No transaction values, share counts, or percentage changes are provided.
• · No scheduled events (e.g., earnings calls, shareholder meetings) are mentioned.

29-07-2026

Catalyst Acquisition Corp., a blank check company, announced the pricing of its $200 million initial public offering of 20,000,000 units at $10.00 per unit, with units trading on Nasdaq under the symbol "CATLU" starting July 28, 2026. The offering is expected to close on July 29, 2026, and the company intends to focus on acquisition opportunities in traditional and digital media sectors, including video games and mobile gaming. The company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 units to cover over-allotments.

• · The units will trade on Nasdaq under the symbol "CATLU" starting July 28, 2026.
• · The Class A ordinary shares and rights are expected to begin separate trading no later than the 52nd day following the IPO date, under symbols "CATL" and "CATLR" respectively.
• · Santander is acting as sole book-running manager for the offering.
• · The company is a blank check company formed to pursue a business combination, with a focus on traditional and digital media sectors including video game companies, mobile gaming, publishers, studios, and media platforms.
• · The registration statement for the securities became effective on July 27, 2026.

29-07-2026

Xencor announced a settlement agreement with Alexion to resolve a commercial dispute over U.S. royalties on Ultomiris. Under the agreement, Xencor will receive $105 million in two equal payments ($52.5 million in August 2026 and $52.5 million one year later), and Alexion will have no further U.S. royalty obligations. Ex-U.S. royalties remain unchanged, and Xencor now expects its cash runway to extend through 2028.

• · The dispute was previously disclosed in March 2026 when Alexion informed Xencor that no additional U.S. royalties were owed.
• · Xencor expects to continue receiving royalties on ex-U.S. sales of Ultomiris under existing license terms.
• · Guidance for year-end 2026 cash, cash equivalents, and marketable debt securities will be updated with Q2 2026 financial results.
• · Xencor is a clinical-stage biopharmaceutical company with more than 20 candidates engineered with XmAb technology in clinical development.

29-07-2026

MIMEDX Group, Inc. (MDXG) announced a definitive merger agreement to acquire Sanara MedTech Inc. (SMTI) in a cash-and-stock transaction valued at $35 per share, with a total enterprise value of approximately $350 million. The deal is expected to nearly double MIMEDX's surgical revenue, be immediately accretive to revenue growth, gross margin, and Adjusted EBITDA margin, and generate over $20 million in run-rate cost synergies. However, the transaction is subject to shareholder and regulatory approvals, and MIMEDX will take on $300 million in new debt to finance the cash portion, increasing its leverage.

• · The transaction has been unanimously approved by the boards of both companies.
• · Closing is expected by end of 2026, subject to Sanara shareholder approval, regulatory approvals, and other customary conditions.
• · MIMEDX's existing credit agreement will be terminated and all amounts outstanding repaid upon closing of the new debt financing.
• · Sanara is working towards a 2027 commercial launch of OsStic BioAdhesive Advanced Bone Fixation, a Breakthrough Device designated by the FDA.
• · MIMEDX also issued a separate press release for its Q2 2026 results; a conference call is scheduled for July 29, 2026 at 4:30pm EDT.

29-07-2026

Medalist Diversified REIT, Inc. completed the acquisition of a 1.64-acre automotive service property in Overland Park, Kansas for $5.8 million in cash on July 29, 2026. The property was acquired through a Delaware statutory trust (DST), and the company plans to offer beneficial interests in the DST to accredited investors in a private placement, with proceeds used to redeem the company's interests. The acquisition was funded from cash on hand, and no debt or equity issuance was involved.

• · The acquisition was previously disclosed in a Form 8-K filed on June 9, 2026.
• · The seller was unaffiliated, and the transaction was at arm's length.
• · The DST was formed specifically to acquire and hold title to the property.
• · Financial statements and pro forma financial information will be filed within 71 days of this report.

29-07-2026

Nabors Industries Ltd. announced its subsidiary Nabors Industries, Inc. received a waiver from lenders (including Citibank, Wells Fargo, Morgan Stanley, HSBC, Goldman Sachs) to redeem up to $100.0 million of its 9.125% senior notes due 2030, temporarily suspending debt repayment restrictions under its credit agreement. The waiver is limited to this redemption and does not modify other loan terms; the company represented no defaults exist. The filing shows proactive debt management but does not provide financial performance or segment data, so a balanced view on operational health cannot be assessed.

• · The waiver is effective as of July 23, 2026.
• · The waiver is limited solely to the Partial Redemption and does not affect other loan document obligations.
• · Representations and warranties under the Credit Agreement remain true and correct.
• · No Event of Default or Default exists as of the waiver effective date.
• · The waiver was executed by Required Lenders, including major banks.

29-07-2026

Silver Bow Mining Corp. appointed Doug Stiles as President, effective July 27, 2026. Stiles, previously Vice President of Regulatory and External Affairs, brings over 25 years of Montana mining experience to lead the flagship Rainbow Block Project. The filing is a routine leadership update with no financial results or negative disclosures.

• · Stiles holds a BS in environmental engineering from Montana Technological University and an MBA from Washington State University.
• · He previously served as Director of Environmental Operations for Hecla Mining Company and General Manager of Hecla Montana.
• · The Rainbow Block Project is located entirely on private patented lands under Montana DEQ jurisdiction.
• · Stiles has experience permitting, developing, operating, and remediating the Rock Creek, Montanore, and Troy Mine projects in Montana.

29-07-2026

AXT, Inc. announced a long-term supplier agreement with Lumentum Operations, LLC for the supply and capacity reservation of indium phosphide wafer substrates through December 31, 2031. Lumentum will pay an initial deposit of $43,500,000 within thirty business days and a second deposit of $43,500,000 with timing to be determined in 2028, which will be applied as shipment credits. The agreement secures a minimum annual commitment from Lumentum and positions AXT as a key supplier for indium phosphide requirements over the coming years.

• · The agreement runs from entry through December 31, 2031.
• · Deposits will be applied as shipment credits towards product purchases until exhausted.
• · AXT has agreed to support any additional capacity that may be required beyond the minimum annual commitment.
• · AXT has partial ownership in ten companies in China producing raw materials for its manufacturing process.

29-07-2026

MiMedx Group, Inc. (MDXG) announced a definitive merger agreement to acquire Sanara MedTech Inc. (SMTI) for $35 per share in a cash-and-stock transaction valued at approximately $350 million enterprise value, representing a 46% premium to Sanara's 30-day VWAP. The deal is expected to close by end of 2026, nearly double MiMedx's surgical revenue, and be immediately accretive to revenue growth, gross margin, and Adjusted EBITDA margin. However, the transaction is subject to Sanara shareholder approval, regulatory clearances, and other customary conditions, and MiMedx will take on $300 million in new debt financing to fund the cash portion.

• · Sanara is working towards a 2027 commercial launch of OsStic BioAdhesive Advanced Bone Fixation, a Breakthrough Device designated by the FDA.
• · MiMedx's existing credit agreement will be terminated and all amounts outstanding repaid in full upon closing of the Hayfin debt financing.
• · The transaction has been unanimously approved by the boards of both companies.
• · A conference call to discuss the transaction and MiMedx's Q2 2026 results is scheduled for July 29, 2026 at 4:30pm EDT.
• · The combined 2027 total revenue is expected to be well in excess of $400 million with an Adjusted EBITDA margin over 20%.
• · No prior-period financial data is provided for comparison; all forward-looking projections are unverified.

29-07-2026

Equinix entered into a new $5.5B senior unsecured multi-currency revolving credit facility on July 27, 2026, replacing its prior 2022 credit agreement. The facility matures in July 2031 and includes sublimits for Swiss Franc and Euro borrowings, as well as a $1.5B sublimit for letters of credit and bank guarantees. The company repaid and terminated the 2022 credit agreement on the same date.

• · The facility includes a financial covenant requiring consolidated net funded debt to consolidated adjusted EBITDA ratio not greater than 6.50 to 1.00, temporarily increaseable to 7.00 to 1.00 following material acquisitions.
• · Borrowings under the facility can be used for working capital, capital expenditures, acquisitions, dividends, distributions, stock buybacks, and letters of credit.
• · The Applicable Margin for Base Rate borrowings was zero as of the closing date.
• · The facility fee ranges from 7.0 to 20.0 basis points based on Equinix's consolidated net leverage ratio or credit ratings.

29-07-2026

Cadre Holdings, Inc. filed an 8-K on July 29, 2026, reporting entry into a material definitive agreement (Item 1.01) and creation of a direct financial obligation (Item 2.03). The filing does not disclose the counterparty, dollar value, or strategic rationale, limiting the ability to assess materiality. No financial metrics, guidance, or scheduled events are provided.

• · Filing date: July 29, 2026
• · AccNo: 0001104659-26-088148
• · Size: 587 KB
• · Sector: not specified

29-07-2026

Adaptive Biotechnologies reported Q2 2026 revenue of $71.6M (+22% YoY), driven by MRD revenue of $66.2M (+33% YoY) and clonoSEQ test volume growth of 43% to 36,111 tests. However, Immune Medicine revenue declined 40% YoY to $5.4M, and GAAP net loss widened to $39.9M from $25.6M in Q2 2025, largely due to a $23.7M loss on extinguishment of the OrbiMed Purchase Agreement. The company raised full-year MRD revenue guidance to $268M-$278M and announced plans to separate its MRD and Immune Medicine businesses, while CSO Harlan Robins transitions to a strategic consultant role.

• · Revenue from Genentech Agreement was zero in Q2 2026 vs. contributing in Q2 2025.
• · Excluding Genentech, Immune Medicine revenue grew 8% YoY, masking the headline 40% decline.
• · Interest and other income, net was $2.3M in Q2 2026 vs. $2.4M in Q2 2025.
• · Interest expense was $2.7M in Q2 2026 vs. $2.9M in Q2 2025.
• · Net loss per share (basic and diluted) was $(0.25) in Q2 2026 vs. $(0.17) in Q2 2025.
• · Full-year 2026 total company operating expense guidance narrowed to $350M-$355M from $350M-$360M.
• · Cash and marketable securities of $371.7M includes $15.1M held by Digital Biotechnologies, Inc.
• · The company completed a $345M zero-coupon convertible senior notes offering and repaid the OrbiMed Purchase Agreement.
• · Harlan Robins is transitioning from CSO to a strategic consultant role focused on MRD R&D and the Immune Medicine separation.

29-07-2026

Owens Corning announced the appointment of Jonathan M. Collins as EVP and CFO, effective August 10, 2026, with a base salary of $775,000 and a target annual cash incentive of 100% of base salary. Concurrently, Todd W. Fister was promoted from EVP, CFO and COO to President and COO, while Brian D. Chambers remains CEO. The company also granted retention awards of $1 million each to the Presidents of Roofing and Doors to ensure leadership continuity.

• · Jonathan M. Collins, age 47, previously served as EVP and CFO of Clarivate Plc since December 2021, and before that as EVP and CFO of Dana Incorporated from 2016 to 2021.
• · Todd W. Fister, age 52, has been with Owens Corning since at least 2018, serving as EVP, CFO and COO since May 2026, and previously as EVP, CFO from September 2023 to May 2026.
• · The retention awards to Nicolas Del Monaco and Rachel Marcon are in the form of RSUs that cliff vest after three years, subject to continued service.
• · The initial equity award to Collins includes performance share units with a target of $1.5M (0% to 200% payout based on 2026-2028 performance criteria), $1M RSUs cliff vesting at 30 months, and $2M RSUs vesting 50% at 1 year and 50% at 18 months.
• · Collins' sign-on bonus of $500,000 must be fully repaid if he voluntarily terminates employment within 12 months of the effective date.
• · The severance agreement provides cash severance equal to two times base salary plus target annual incentive (reduced to one times under certain conditions), plus health insurance and outplacement assistance, subject to a one-year non-compete and non-solicitation.

29-07-2026

Clarivate Plc announced the appointment of Michael Easton as Executive Vice President and Chief Financial Officer, effective August 8, 2026, succeeding Jonathan Collins who is stepping down. Easton, a tenured finance executive and former Chief Accounting Officer, brings over 25 years of experience. The company also reported its Q2 2026 financial results in a separate press release issued the same day, though specific financial figures were not included in this filing.

• · Michael Easton most recently served as SVP and Chief Accounting Officer, leading core financial reporting and planning functions.
• · Jonathan Collins is stepping down to pursue another opportunity.
• · The outgoing CFO is credited with bringing rigor to financial management and executing the planned divestiture of the Life Sciences & Healthcare segment.
• · Easton previously spent more than 14 years with Ernst & Young and holds bachelor's and master's degrees in accounting from Brigham Young University.
• · A separate press release issued today reported Q2 2026 financial results; a conference call and webcast are scheduled for 9:30 AM ET.

29-07-2026

Better Home & Finance Holding Co announced the resignation of director David Barse, effective July 27, 2026, with no disagreement with the company, and the immediate election of Daniel Lewis to the board. Mr. Lewis will serve until the 2027 annual meeting and participate in the standard non-employee director compensation program. No committee assignments have been made yet.

• · David Barse's resignation was not due to any disagreements with the company on operations, policies, or practices.
• · Daniel Lewis has no family relationships with any director or executive officer and no material interest in any reportable transaction.
• · Mr. Lewis will enter into the company's standard indemnification agreement.

29-07-2026

Allbirds, Inc. (Smartbird, Inc.) dismissed Deloitte & Touche LLP as its independent auditor on July 28, 2026, and engaged BPM LLP as its new independent registered public accounting firm for fiscal year 2026. The change was approved by the Audit Committee following a competitive RFP process. No disagreements or reportable events occurred with Deloitte during the past two fiscal years or the subsequent interim period.

• · Deloitte's audit reports for fiscal years ended December 31, 2025 and 2024 were unqualified and contained no adverse opinion or disclaimer.
• · No disagreements or reportable events occurred with Deloitte during the two most recent fiscal years or the interim period from January 1, 2026 to July 28, 2026.
• · The company did not consult BPM on any accounting, auditing, or financial reporting issues prior to engagement.
• · Deloitte provided a letter dated July 28, 2026, agreeing with the disclosures in the 8-K, filed as Exhibit 16.1.

29-07-2026

Procore Technologies announced a definitive agreement to acquire DroneDeploy for approximately $845 million in cash. The acquisition aims to integrate DroneDeploy's aerial and ground reality capture and robotics capabilities into the Procore platform, enabling AI-powered insights and autonomous actions on construction jobsites. The transaction is expected to close later in 2026, subject to regulatory approvals, and Procore's financial outlook does not include contributions from DroneDeploy.

• · Procore's financial outlook issued today represents its organic business and does not reflect contributions from DroneDeploy.
• · Goldman Sachs & Co. LLC is serving as exclusive financial advisor to Procore; Citi is serving as financial advisor to DroneDeploy.
• · The acquisition is expected to close later in 2026, subject to customary closing conditions and regulatory approvals.

29-07-2026

Kohl's announced the retirement of Chair John Schlifske after 15 years of service, with Wendy Arlin unanimously elected as the new Chair effective immediately. The company also appointed Niren Chaudhary, former Panera Brands CEO and Chair, as an independent director. The leadership changes are part of an ongoing board refreshment process, with no financial metrics or performance data disclosed in the filing.

• · Wendy Arlin has served on Kohl's Board since December 2023 and chaired the Finance and Audit Committees since May 2025.
• · Niren Chaudhary's term expires at Kohl's 2027 annual shareholders' meeting, and he will serve on the Audit Committee.
• · Chaudhary previously oversaw 130,000 associates across nearly 4,000 locations as CEO of Panera Brands.
• · Arlin held leadership roles at L Brands for nearly 20 years and served as CFO of Bath & Body Works from August 2021 to July 2023.
• · Chaudhary is also a Board Director for SIG Group AG and serves on its Compensation and Nomination/Governance Committees.

29-07-2026

Splash Beverage Group expanded its exclusive global license for CannEpil® to include veterinary therapeutic applications, establishing a second FDA-regulated pharmaceutical development program alongside its existing human program. The expansion positions CannEpil for companion-animal oncology and chronic pain management, with canine indications as the initial focus, targeting a global veterinary pain management market projected to grow from ~$2.6B in 2024 to ~$3.8B by 2030. However, the company faces significant regulatory and development risks, including no assurance of FDA approval or successful commercialization, and continues to rely on capital raises and strategic partnerships to execute its strategy.

• · The expanded license grants Splash exclusive worldwide rights to develop, manufacture, commercialize, market and distribute CannEpil for veterinary diseases and conditions.
• · Splash will pay Argent BioPharma Limited a 10% royalty on net revenues from veterinary applications of CannEpil.
• · CannEpil has been assigned an IND application number by the FDA for its human development program.
• · The company is finalizing a strategic joint venture with an established cannabinoid pharmaceutical company to lead CannEpil’s veterinary development program; the partner’s executives have a track record of advancing cannabinoid medicines through regulatory approval and commercialization.
• · There is no assurance that CannEpil will receive Conditional Approval, full approval, or any other regulatory authorization for veterinary use, or that any commercialization efforts will be successful.
• · The company continues to face capital needs and compliance risks, as noted in the forward-looking statements and risk factors.

29-07-2026

Addentax Group Corp. entered into a Private Placement Agreement with Pinnacle Partners Inc. on July 28, 2026, to issue and sell 250,000 shares of common stock at $4.80 per share for aggregate gross proceeds of approximately $1.2 million. The offering is exempt from registration under Regulation S and is expected to close upon satisfaction of customary conditions. The filing does not provide any period-over-period comparisons or financial performance data.

• · The shares will bear customary restrictive legends under the Securities Act.
• · The investor is not a 'U.S. person' as defined in Regulation S.
• · The offering is expected to close in an offshore transaction.

29-07-2026

Tronox Holdings plc announced a quarterly dividend of $0.05 per share, payable on October 9, 2026 to shareholders of record on August 10, 2026. The dividend declaration reflects the company's ongoing commitment to returning capital to shareholders, though the amount is modest relative to its market cap.

• · Dividend payable on October 9, 2026 to shareholders of record on August 10, 2026.
• · Tronox is the world's leading integrated manufacturer of titanium dioxide pigment.
• · Company has approximately 5,700 employees across six continents.

29-07-2026

Entegris announced the appointment of Robert A. Bruggeworth, President and CEO of Qorvo, to its Board effective August 3, 2026, and the retirement of Executive Chair Bertrand Loy on July 31, 2026, with Lead Independent Director James F. Gentilcore becoming Chair. The changes reflect the culmination of the CEO succession plan following Dave Reeder's appointment as CEO in 2025, bringing the total board size to eight members.

• · Robert A. Bruggeworth has served as President and CEO of Qorvo since 2015 and previously led RFMD for nearly 10 years.
• · Bertrand Loy served as President and CEO for 13 years before becoming Executive Chair.
• · Dave Reeder was appointed CEO in 2025 as part of the succession plan.
• · Entegris is ISO 9001 certified and has facilities in the US, Canada, China, Germany, Israel, Japan, Malaysia, Singapore, South Korea, and Taiwan.

29-07-2026

OS Therapies Inc. terminated its At Market Issuance Sales Agreement with B. Riley Securities and JonesTrading Institutional Services, effective July 28, 2026. The company had raised only approximately $530,162 in gross proceeds from the $18,000,000 facility, leaving about $17,469,838 unsold. No termination fees were incurred.

• · The Sales Agreement was dated August 8, 2025, and a prospectus supplement was filed on August 25, 2025.
• · The termination notice was delivered on July 23, 2026, and the termination became effective on July 28, 2026.
• · No termination fees or other payments were due by either party.

29-07-2026

Golden Matrix Group, Inc. (GMGI) announced the separation of CFO Rich Christensen effective July 31, 2026, with a $30,000 severance payment and a consulting agreement to follow. The separation is amicable and not for cause, but the departure of a key officer introduces leadership transition risk. No successor CFO has been named in the filing.

• · The separation is effective July 31, 2026, unless another date is mutually agreed.
• · Christensen will continue as a consultant under a separate Independent Consulting Agreement (ICA).
• · The severance payment is conditioned on full handover of bank accounts, Nasdaq filing accounts, and other logins.
• · Christensen waives all claims against the company, including under ADEA and other employment laws, but retains whistleblower rights with the SEC.
• · The company must file required forms with stock exchanges and the SEC to notify of the CFO departure, subject to Christensen's pre-approval (deemed approved if no response within 48 hours).
• · No other compensation (bonuses, stock awards, commissions) is due beyond the severance and PTO reimbursement.
• · Christensen may be eligible for a discretionary bonus if he remains with the company in 2027 when 2026 results are reported (consulting services do not count as remaining).

29-07-2026

NextNRG, Inc. entered into a Securities Purchase Agreement on July 24, 2026, with multiple investors, issuing securities in a private placement exempt under Section 4(a)(2) and Rule 506(b) of Regulation D. The company has 168,133,448 shares of common stock outstanding and 140,000 shares of Series B Preferred Stock issued and outstanding, with no Series A Preferred Stock outstanding. The filing includes extensive representations and warranties regarding the company's financial condition, compliance, and capitalization, but does not disclose the specific amount raised or the terms of the securities issued.

• · The company has 505,000,000 total authorized shares of capital stock.
• · No shares of Common Stock are reserved for issuance pursuant to Convertible Securities (other than the Notes).
• · The company represents it is not insolvent and has not taken steps toward bankruptcy.
• · The company represents compliance with the Sarbanes-Oxley Act and the Foreign Corrupt Practices Act.
• · The filing redacts certain non-material confidential information under Item 601(b)(10)(iv).

29-07-2026

InspireMD, Inc. eliminated the position of Chief Commercial Officer Shane Gleason, effective July 31, 2026. The filing does not provide any financial or operational metrics, so no positive or negative performance data is available.

• · The position elimination was effective July 23, 2026, with last day of employment on July 31, 2026.
• · The filing includes no financial impact, severance details, or replacement plans.